Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Tularik gets $35M from Amgen investment

AMGN invested $35 million in TLRK through the purchase

Read the full 94 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE